Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
The clinical manifestations of uremia are only incompletely reversed by chronic hemodialysis. Signs and symptoms can include abnormalities in electrophysiologic indices, clinical mental status, and neuropsychological test performance, as well as decreases in exercise tolerance, sexual potency, and general quality of life. Though retention of uremic toxins is responsible for many of these symptom complexes, some may be caused, or substantially aggravated, by the anemia that almost invariably accompanies chronic renal failure. Treatment with recombinant human erythropoietin (r-HuEPO; EPOGEN [epoetin alfa], AMGEN Inc, Thousand Oaks, CA) increases hematocrit values and thus reduces the anemia, in turn improving brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
Nissenson
A R
AR
Department of Medicine, UCLA School of Medicine 90024.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003071:Cognition; D004921:Erythropoietin / Q000627:therapeutic use*; D015444:Exercise; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D012723:Sex
D011994:Recombinant Proteins; D004921:Erythropoietin